| Publications | PubMed=830403
Goss P.D., Parsons P.G.
The effect of hyperthermia and melphalan on survival of human fibroblast strains and melanoma cell lines.
Cancer Res. 37:152-156(1977) PubMed=294576; DOI=10.3109/00313027909059039
Muir P.D., Gunz F.W.
A cytogenetic study of eight human melanoma cell lines.
Pathology 11:597-606(1979) PubMed=460945; DOI=10.3109/00313027909061945
Pope J.H., Morrison L.E., Moss D.J., Parsons P.G., Dunne R.M.
Human malignant melanoma cell lines.
Pathology 11:191-195(1979) PubMed=1697409
Chenevix-Trench G., Martin N.G., Ellem K.A.O.
Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53.
Oncogene 5:1187-1193(1990) PubMed=9354451
Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M., Gabrielli B.G., Parsons P.G., Hayward N.K.
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997) PubMed=10070891; DOI=10.1038/sj.bjc.6690147
Zerp S.F., van Elsas A., Peltenburg L.T.C., Schrier P.I.
p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis.
Br. J. Cancer 79:921-926(1999) PubMed=15048078; DOI=10.1038/sj.onc.1207563
Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M., Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L., Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G., Meltzer P.S., Ringner M., Hayward N.K.
Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Oncogene 23:4060-4067(2004) PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152
Stark M.S., Hayward N.K.
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
Cancer Res. 67:2632-2642(2007) PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x
Johansson P., Pavey S., Hayward N.K.
Confirmation of a BRAF mutation-associated gene expression signature in melanoma.
Pigment Cell Res. 20:216-221(2007) PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676
Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V., Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M., Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.
A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.
Mol. Cancer Ther. 11:888-897(2012) PubMed=23039341; DOI=10.1186/1476-4598-11-75
Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J., Nomoto K., Pollock P.M.
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol. Cancer 11:75.1-75.15(2012) |
|---|